PBLS

MKT CAP:$4B

Parabilis Medicines, Inc. Common Stock

Market Cap

$4B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$29.58-$2.02 (-6.39%)

Jul 2, 2026

52W High $31.6052W Low $25.01

Company Details

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon disc...

Leadership

Mathai Mammen M.D., Ph.D.

CEO, President, Treasurer & Chairman

Teresa L. Jurgensen J.D.

Executive VP, Secretary & General Counsel

Mohammed Fawzi Benzaghou M.D.

Chief Medical Officer

John McGee Ph.D.Founder

Scientific Co-Founder, Executive Vice President & Head of Platform

Thomas Rodolpho Kotarakos

Chief Financial Officer

Rohin Mhatre Ph.D.

Chief Technical Operations Officer

Jianing Di Ph.D.

VP of International R&D and Corporate Development

Kristen Stants

Chief People Officer

Jonathan Hurov Ph.D.

Executive Vice President of Discovery Biology

Marie Nguyen M.D.

Senior VP & Head of Clinical Development

IPO Date

—

Website

parabilismed.com

Key Metrics TTM

Revenue

- YoY

Net Income

-$45M

EPS (Diluted)

Free Cash Flow

-$50M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Revenue & Profitability

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee